NEW DELHI: Unrelenting pricing pressure on generics in the US and attractive global opportunities have led domestic majors including Ranbaxy, Dr Reddy’s and Glenmark to find niches such as biotechnology. While for some — Nicholas Piramal and Dishman, contract research and manufacturing services has emerged as a huge opportunity, others like Divi’s Laboratories have forayed into neutraceuticals. >>> Discuss This Story
